Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for June 2010
June 2, 2010
- Phase 2 Clinical Trial Data Show Significant Improvements in Outcomes and Symptoms in Advanced Heart Failure Patients Treated with Celladon's Genetically Targeted Enzyme Replacement Therapy MYDICAR
- Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
- FAIR-HF Subanalysis Shows That Ferinject Improves Kidney Function in Iron-Deficient Patients With Chronic Heart Failure
- Phase 3 Data on VIVUS' Avanafil for Erectile Dysfunction to be Featured at the AUA 2010 Annual Meeting
- Relevare Pharmaceuticals Presents Latest Clinical Trial Data on CNSB015 at Third International Congress on Neuropathic Pain in Athens, Greece
June 3, 2010
- Nat'l Scientific Psychiatry Mtg: Study Evaluated Vyvanse Efficacy and Safety in Adolescents with ADHD
- Angiotech's licensee, Cook Medical, announces single-arm study reveals 86. 2 percent SFA vessel patency for Zilver PTX
June 4, 2010
- Oncolytics Biotech Inc. to Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
- BioAlliance Pharma presents preclinical results for its AMEP biotherapy in the treatment of invasive melanoma supporting ongoing phase I clinical trial
- Idera Pharmaceuticals Announces Publication of Preclinical Data on Cancer Immunotherapy with its Dual Agonist of Toll-like Receptors 7 and 8
- ARIAD Announces Recommendation of Data Monitoring Committee Following Second Interim Analysis of Phase 3 Succeed Trial of Oral Ridaforolimus, an Investigational mTOR Inhibitor, in Metastatic Sarcomas
- Bayer Presents Clinical Data on Alpharadin in Metastatic Castration-Resistant Prostate Cancer (CRPC)
- New AMG 479 Phase 2 Data Show Antitumor Activity in Patients With Metastatic Pancreatic Cancer
- New Docs Linked to Death Spike in July
- Novartis International AG (CH) - Pivotal Phase III trial of Novartis drug Afinitor met primary endpoint in study of patients with advanced pancreatic neuroendocrine tumors
- Pacific Edge Announces Successful Completion of Colorectal Cancer Prognostic Clinical Trial
- Angiochem to Present Data for ANG1005 at American Society for Clinical Oncology Meeting
- Syndax Pharmaceuticals' Entinostat Shows Clinical Promise in Patients with Advanced Hormone Refractory Breast Cancer
- Teva Announces Positive Results from a Study Assessing a New Formulation of Copaxone
- Stroke Prevention Study in Children with Sickle Cell Anemia, Iron Overload Stopped Early
- R-Tech Ueno Discloses Results of Phase 2 Retinitis Pigmentosa Clinical Trial
- Agendia Presents Broad Array of Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO 2010 Annual Meeting
- Neuralstem ALS Trial Principal Investigator To Speak At Brookings Institution
- Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
June 5, 2010
- Second-line CML Drug Evokes Faster Response, Fewer Side Effects, Pivotal Study Finds
- SPRYCEL (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
June 7, 2010
- Keystone Symposium Highlights Positive Preclinical Data on Novel Immune Modulator
- Inovio Biomedical to Present at Vaccine Technology III Conference
- VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Diabetics With Erectile Dysfunction
- Geron Presents Clinical Data on Its Telomerase Inhibitor Drug in Breast Cancer at ASCO
- ARIAD Presents Updated Clinical Data on Its Investigational Pan-BCR-ABL Inhibitor, AP24534, in Drug-Resistant Chronic Myeloid Leukemia
- Dyax Announces Publication of Kalbitor (ecallantide) Edema4 Trial Results in the Annals of Allergy, Asthma, and Immunology
- New treatment for major cause of vision loss in diabetes more effective than current standard of care
- Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
- 'Remote control' for cholesterol regulation discovered in brain
- Oncolytics Biotech Inc. Collaborators Present Positive Updated U.K. Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the ASCO Annual Meeting
- XenoPort Announces Presentations of Data for Arbaclofen Placarbil and XP13512 at the Associated Professional Sleep Society Meeting
- Phase III Study Results Showed Eisai's Eribulin Mesylate Significantly Improved Overall Survival in Patients with Locally Recurrent or Metastatic Breast Cancer
- First Phase III Trial With Definitive Results In Advanced Medullary Thyroid Cancer Shows Statistically Significant Extension of Progression Free Survival For Patients
- Investigational Compound Ipilimumab Demonstrates Improved Overall Survival in Phase 3 Trial of Previously-Treated Patients with Metastatic Melanoma
- OncoGenex Pharmaceuticals Announces Final Results from Phase 1 Trial Evaluating OGX-427 as a Treatment for Solid Tumors
- Phase 3 Study Showed Macugen Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema
- Oncothyreon Announces Presentation of Phase 1 Data for PX-866 and PX-478 at American Society of Clinical Oncology Annual Meeting
- Study Reveals Survival Benefit for Patients with Inoperable Hepatocellular Carcinoma (HCC) treated with a Unique Combination of Radioactive Microspheres and Standard-of-Care Systemic Therapy
- Phase III Study Showed Avastin-Based Regimen Helped Women with Advanced Ovarian Cancer Live Longer Without Their Disease Worsening
- Avid Radiopharmaceuticals to Present at the Inaugural Jefferies Global Life Sciences Conference on June 10th
- Celldex Therapeutics Presents New Clinical Data from Phase 2 Study of CDX-011 in Metastatic Melanoma at 46th Annual ASCO Meeting
- Synta Announces Encouraging STA-9090 Clinical Results Presented at ASCO
- Progenics Phase 1 PSMA ADC Study Presented in New ?Trials in Progress? Poster Session at ASCO Annual Meeting
- Angiochem Presents Complete Phase 1 /2 Clinical Data for ANG1005: Further Demonstrating Benefits of Targeting LRP-1 Pathway in Cancer
- Non-Melanoma Skin Cancer May Help Identify Survivors at Increased Risk for Future Cancers
- Exelixis Reports Updated Data from Multiple Clinical Trials of the PI3K Inhibitor XL147 (SAR245408) to be Presented at ASCO
- Alnylam Presents Preliminary Phase I Data at American Society of Clinical Oncology (ASCO) Meeting for ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancers
- Data Presented from Two Phase 3 Erbitux Studies in First-Line Metastatic Colorectal Cancer Patients at Joint 15th European Cancer Organisation and 34th European Society for Medical Oncology Multidisciplinary Congress
- ImmunoGen, Inc. Announces Encouraging IMGN388 Clinical Data Reported at ASCO
- Micromet Presents Interim Update on Phase 1 Study of MT110 in Patients with Advanced Solid Tumors
- Aeterna Zentaris Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors, Including Patients with Advanced Brain Tumors and Neuroblastoma
- Celator Pharmaceuticals Announces Data on Remissions With CPX-351 Following Induction Failure
- Keryx Biopharmaceuticals Announces Phase 1 Data of Single Agent Perifosine in the Treatment of Recurrent Pediatric Solid Tumors, Including Patients with Advanced Brain Tumors and Neuroblastoma
- Tesetaxel Results from Two Clinical Dose-Ranging Trials Presented at ASCO
- Drug That Helps Metastatic Colon Cancer of No Benefit in Less Advanced Tumors
- Landmark Study Confirms Grazax as the Only Grass Allergy Immunotherapy Tablet to Show Sustained Effect 2 Years After Treatment Completion
- Phase II Clinical Trial Results of 'ADI-PEG 20' Show Efficacy in Human Metastatic Melanoma Deficient in a Key Metabolic Enzyme, and in Lymphomas in Preclinical Studies
- ThromboGenics Presents New Exciting Microplasmin Phase III Data at the World Ophthalmology Congress (WOC) in Berlin
- Provectus Reports Encouraging Data on Visceral Metastases Presented at ASCO
- Aeterna Zentaris Presents Positive Efficacy and Safety Data for AEZS-108 in Ovarian Cancer at ASCO Meeting
- OPAXIO Phase II Study Results Confirm High Rate of Complete Response with Low Rate of Side Effects in Patients with Advanced Esophageal Cancer
- GTx Presents Additional Study Results in Quality of Life Improvements from the Phase IIb Clinical Trial Evaluating Ostarine for Cancer Induced Muscle Wasting
- AVEO Pharmaceuticals' Tivozanib Demonstrates Progression-Free Survival of 14.8 Months in Subgroup of Patients with Advanced Kidney Cancer; Extended Duration of Treatment Continues to Highlight Favorable Tolerability Profile
- U of M study: Monitoring cholesterol increases life expectancy
- New Clinical Data on Millennium Solid Tumor Compounds Presented at American Society of Clinical Oncology
- ZIOPHARM Presents Positive Palifosfamide PICASSO Phase II Results in Oral Session at ASCO
- WILEX presents at ASCO positive final phase II data of MESUPRON in pancreatic cancer
- New Study Demonstrates Improvements in Lupus Patients Receiving Stem Cell Therapies
- Four-Year Follow-Up Data for SPRYCEL (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®1
- Cell>Point to Present Clinical Results in Cancer Molecular Imaging with SPECT at Society of Nuclear Medicine Annual Meeting June 7, 2010
- Levi & Korsinsky, LLP Investigates Possible Breach of Fiduciary Duty by the Board of Talecris Biotherapeutics Holdings Corp. - TLCR
June 8, 2010
- NanoViricides Reports that Antiviral Efficacy was Demonstrated Against Two Different HIV-1 Isolates in Cell Culture Studies, Corroborating Previous Findings in Animal Studies
- GTx Announces Toremifene 80 mg Treatment Demonstrated Improved Fracture Reduction and Safety Profile in Men With Prostate Cancer on ADT Younger Than Age 80
- Genmab Presents Data from a Pivotal Trial of Zalutumumab Versus Best Supportive Care in Patients with Refractory Head and Neck Cancer
- QLT Ophthalmics, Inc. Prepares for Growth with Cloud Computing CRM Solution from Veeva Systems
- PolyMedix to Review Results from Recent Phase 1B LMWH Reversal Clinical Study with Heptagonist PMX-60056
- Idera Pharmaceuticals Announces Preliminary Data from Phase 1 Clinical Trial of IMO-3100, a Toll-like Receptor Antagonist Drug Candidate for Autoimmune and Inflammatory Diseases
- Under 50? Silent Duo Could Put You At Risk For A Big Stroke
- Cost Of Caring For Stroke Patients Double That Of Earlier Estimates
- Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at the 15th Congress of the European Hematology Association
- Lubiprostone Successfully Completes Phase 3 Efficacy Trial in Japanese Patients Suffering from Chronic Idiopathic Constipation
- Telik Announces Positive Phase 2 Results of a Multicenter Study of Ezatiostat Hydrochloride Tablets in Patients with Myelodysplastic Syndrome
- Celsion Announces ThermoDox Abstract Presented at the American Society of Clinical Oncology 2010 Annual Meeting
- Resverlogix Publishes Data Confirming RVX-208's Impact on Reverse Cholesterol Transport
- Aeterna Zentaris Reports Final Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine in the Treatment of Advanced Metastatic Colorectal Cancer
- Among the Toughest Cancers to Treat, New Abaxane Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma
- Argos Therapeutics Presents Positive Phase II Data for Arcelis Dendritic Cell-based Immunotherapy in Advanced RCC at ASCO
June 9, 2010
- Pharmasset Announces Submission of Abstracts to AASLD Liver Meeting Including an Interim Analysis of Roche's Phase 2b PROPEL Trial of RG7128
- Human Genome Sciences Announces Results of Randomized Phase 2 Trial of Mapatumumab in Multiple Myeloma
- Particle Engineering Company Enavail Announces New cGMP Pharmaceutical Manufacturing Facility to Be Located in the Abilene Life Sciences Accelerator
- Vigabatrin/CPP-109 Data to be Presented at College on Problems of Drug Dependence Annual Meeting
- Results Presented from Phase IIb Clinical Study of Merck's Investigational Insomnia Therapy MK-4305
- CoLucid Pharmaceuticals, Inc. Announces Study Data Documenting Oral Efficacy of Lasmiditan (COL-144), a Selective 5-HT1F Receptor Agonist, in the Treatment of Acute Migraine Attacks
- BENZEFOAM Emollient Foam More Effective in Reducing P. acnes Bacteria Than Prescription Benzoyl Peroxide Cleanser
- Discovery Labs Reports Preliminary Results From Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure
- Arcalyst (rilonacept) Meets Primary and All Secondary Endpoints in Phase 3 Trial of Prevention of Gout Flares in Patients Initiating Allopurinol Therapy
- Whitehouse Scientific introduces new certified silica microspheres
- Absorption Systems Launches Express Plus ADME Assays
- Nektar Therapeutics Announces Positive Initial Results from Phase 2 Study of NKTR-102 in Metastatic Breast Cancer
- Horizon Pharma Announces LODOTRA and DUEXA Data to be Presented at the European League Against Rheumatism (EULAR) Annual Congress
- Short People Are More Likely To Develop Heart Disease Than Tall People
- Getting A Grip On Stroke Treatment
- Genzyme and Carl Icahn Reach Agreement
- Xcellerex Announces Groundbreaking for New State-of-the-Art FlexFactory Biomanufacturing Facility
- Astellas Completes Acquisition of OSI Pharmaceuticals
- BioFocus renews C.I.R. (French Research Tax Credit) accreditation
- Stem Cells For First Time Used To Create Abnormal Heart Cells For Study Of Cardiomyopathy
- Merck: Investigational Insomnia Treatment Utilizing Novel Pathway Shows Strong Promise in Phase IIb Study
June 10, 2010
- VBL Therapeutics to Present Data on VB-201 for Rheumatoid Arthritis at EULAR Annual Meeting
- MAP Pharmaceuticals to Present Two New Data Analyses from Levadex Freedom-301 Trial at AHS Annual Meeting
- Access Pharma Presents at the California NanoSystems Institute Conference Focused on Targeted Delivery of RNAi Therapeutics
- New Interim Results From European Patient Survey Add Weight to Expert Call for Greater Clinical Consensus on Breakthrough Cancer Pain
- Novavax Announces Completion of Construction of Vaccine Production Facility in India
- Afrezza Demonstrates Non-Inferiority Compared to Standard Therapy in Controlling Blood Sugar Levels in Type 1 Diabetes Patients
- UCB (BE) - UCB strengthens strategic alliance with Wilex
- Cardinal Health to Expand in Specialty Pharmaceutical Services With Definitive Agreement to Purchase Healthcare Solutions Holding
- Lubiprostone Successfully Completes Phase 3 Efficacy Trial in Japanese Patients
- Best of ASCO Features Three Studies Led by US Oncology Affiliated Physicians
- Study: U.S. at Risk of Losing Global Lead in Medical Innovation
- New System Developed for Early Diagnosis of Alzheimer's Disease
- Active Biotech (SE) - Active Biotech Capital Markets Day
- Beike Biotech Launches New International Stem Cell Venture
- Cytos Biotechnology Ltd and Intercell AG close the sale of the platform technology
June 11, 2010
- Bionovo Announces Publication Describing the Discovery of Distinct Classes of Genes Regulated By Estrogen Receptor Beta
- Trevena Data Showcasing GPCR Biased Ligands Featured at Scientific Conferences
- AVERROES Study of Investigational Agent Apixaban Closes Early Due to Clear Evidence of Efficacy
- European Respiratory Journal Publishes Phase II Study of Investigational Oral Agent Riociguat in Treatment of Pulmonary Hypertension
- Public Release of Alzheimer's Clinical Trial Data By Pharmaceutical Researchers
- Cell Therapeutics Reports New Data Demonstrating That Complete Responses to Pixuvri Are Correlated With Prolonged Survival in Patients With Relapsed or Refractory Aggressive NHL
- Boston Scientific Announces Schedule for Cardiostim World Congress
- Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Analyst & Investor Meeting
- Allos Therapeutics' FOLOTYN Shows Activity and Tolerability in Phase 1 Dose Finding Study in Patients with Relapsed or Refractory CTCL
June 14, 2010
- Phase III Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
- Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar
- Calistoga Pharmaceuticals Presents Preclinical and Clinical Data Supporting Benefit of First in Class, Novel Mechanism of CAL-101, an Oral Delta Isoform-Selective PI3 Kinase Inhibitor
- Aeterna Zentaris to Present Poster on Pharmacological and Toxicological Data on Oral Synthetic Growth Hormone Secretagogue/Ghrelin Receptor Agonist, AEZS-130, at Upcoming ENDO Annual Meeting
- Internationally Known Neuroblastoma Expert Reviews Status in Fighting Challenging Childhood Cancer
June 15, 2010
- Anacor Announces Phase 2b Top-Line Results for AN2728 in Psoriasis
- Early Clinical Experience and Basic Science Support Further Investigation of Soliris (eculizumab) for the Treatment of Patients with Thrombotic Microangiopathy
- DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
- Biovest to Present at Active Immunotherapeutics Forum
- NexMed Announces Pre-Clinical Results Showing That Its Proprietary Calcipotriene Betamethasone Psoriasis Formulation is Bioequvalent to Talconex
- Morria Biopharmaceuticals Announces Positive Safety, Tolerability and Preliminary Efficacy Results for MRX-4 Phase II Study in Allergic Rhinitis at the EAACI Congress
- New Study Showed the Impact of Gastrointestinal Disorders in Patients With Parkinson's Disease
- Metabolic Solutions Development Company to Present Research Findings at Annual American Diabetes Association Conference
- iPierian to Present Data from Induced Pluripotent Stem Cell Program at ISSCR 8th Annual Meeting
June 16, 2010
- UCB (BE) - Cimzia (certolizumab pegol) shows sustained clinical improvements over three years and inhibition of joint progression in patients with rheumatoid arthritis
- Endocrine Society's Annual Meeting to Feature Data on VIVUS' Qnexa
- UCB (BE) - New data from EMBLEM study shows pipeline drug epratuzumab provided significant efficacy for patients suffering from moderate to severe systemic lupus erythematosus
- Santhera Pharmaceuticals Holding AG (CH) - Santhera's Catena Improved Vision in Patients with Leber's Hereditary Optic Neuropathy; Regulatory Submissions Planned in First Half of 2011
- 12-Month Results From DENALI Study Evaluating verteporfin PDT (Visudyne) Combination Therapy
- Curis Announces Genentech's Phase II Clinical Trial Results of GDC-0449 in Combination with Avastin and Chemotherapy in First-Line Metastatic Colorectal Cancer
- Horizon Pharma, Inc. Presents Results of Phase 3 Studies of Lodotra Demonstrating Statistically Significant Improvement in Response in Rheumatoid Arthritis Patients
- Nuon Therapeutics Announces Positive Topline Results from a Phase 2a Study in Hyperuricemia
- New Data Presented from EMBLEM Study for Pipeline Drug Epratuzumab for Patients Suffering from Moderate to Severe Systemic Lupus Erythematosus
- Higher anxiety, depression among women may have basis in cell signals
- DURATION-4 Study Results Released
- Long-term Cimzia (certolizumab pegol) Data Demonstrated Rapid Sustained Improvements in Clinical Outcomes and Quality of Life in Moderate to Severe Rheumatoid Arthritis (RA) Patients
- Scientific American Article Says DNA Vaccines Are Reaching Their Potential
- NIH-Supported Experimental Marburg Vaccine Prevents Disease Two Days After Infection
June 17, 2010
- Human Genome Sciences and GlaxoSmithKline Announce Presentation at EULAR of BLISS-52 Phase 3 SLE Study Results for Benlysta (belimumab)
- Naurex Inc. Presents Positive Clinical Data on Novel Mechanism Antidepressant Candidate GLYX-13 at NCDEU 50th Anniversary Meeting
- New Celebrex (celecoxib) Study Using Novel Endpoint, Published by The Lancet, Contributes to Knowledge of NSAID-Associated Gastrointestinal Adverse Events
- Chelsea Therapeutics Presents Data at 14th International Congress on Parkinson's Disease and Movement Disorders
- Neupro (rotigotine transdermal system) Showed Significant Benefit on Early Morning Motor Control, Sleep and Nocturnal Symptoms in Patients With Parkinson's Disease
- Human Genome Sciences and GlaxoSmithKline Announce Full Presentation at EULAR of BLISS-76 Phase 3 Study Results for Benslyta in Systemic Lupus Erythematosus
- Neupro® (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson's disease
- Positive Clinical Findings Presented on XOMA 052 in Debilitating Eye Disease
- DURECT Reports Data From European Phase IIb Hysterectomy Study of Posidur (SABER-Bupivacaine)
- Benitec Limited HIV/AIDS Stem Cell Clinical Trial Results Published In Science-Translational Medicine
- Very Small Embryonic-Like Stem Cell Mobilization Data Presented at International Society for Stem Cell Research Annual Meeting
- New Data Presented At ECFS Conference Highlight Potential for Denufosol to Provide Benefit to Adolescent Cystic Fibrosis Patients and Patients on Minimal Pharmacotherapies
June 18, 2010
- Artificial Pancreas can Prevent the Development of Hypoglycemia
- Positive Phase 2 Data on RDEA594, Ardea Biosciences' Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology
- Novartis International AG (CH) - New Phase II study in gout patients shows Novartis ACZ885 prevented acute flares better than standard anti-inflammatory therapy
- BioSante Pharmaceuticals, Inc. to Present LibiGel Safety Update at ENDO Annual Meeting
- Adolor Says Pain Drugs Failed In Midstage Trial
- Adolor Corporation Provides Clinical Update; Will Host Conference Call
- InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting
- Neupro (Rotigotine Transdermal System) Significantly Improved Wellbeing and Daily Activities Impaired Due to Limb Pain Associated With Restless Legs Syndrome
- Heart Bypass Patients Improve Significantly with Adult Stem Cell Infusion Reports TCA Cellular Therapy at ISSCR Meeting in San Francisco, CA
- NexBio and Weill Cornell Medical College Publish Preclinical Study Showing DAS181 (Fludase) Anti-Influenza Drug Inhibits Parainfluenza Virus
June 21, 2010
- Aeterna Zentaris Presents Positive Data at ENDO Meeting on AEZS-130, a Ghrelin Mimetic for Diagnostic and Therapeutic Use
- Anti-Dengue Nanoviricides Achieve Significant Protection in Initial In Vivo Studies on Dengue Hemorrhagic Fever
- GTx Announces Ostarine Increased Lean Body Mass and Leg Press Strength in Head to Head Clinical Study
- Bionomics Anti Anxiety Compound BNC210 Phase Trial Successful
- NicOx: Presentations at EULAR congress
- Cerenis to Present Clinical Proof-of-Concept Results for CER-627 program (niacin/aspirin combinations) at the European Atherosclerosis Society Congress June 20-23
- Affymax and Takeda Announce Phase 3 Trials Meet Primary Endpoints for Investigational Drug, Hematide?/peginesatide, to Treat Anemia in Chronic Renal Failure With Some Differences Noted in Secondary Analyses
- BioSante Pharmaceuticals Reports Positive LibiGel Safety Data in Phase III Clinical Program
- New Head-to-Head Phase 3 Study Evaluated Systolic Blood Pressure Reduction of Investigational Compound Azilsartan Medoxomil Compared to Valsartan
- Semafore Pharmaceuticals Presents New Clinical Data on Novel Prodrug Dual PI3K-mTOR Inhibitor in B-Cell Malignancies and Solid Tumors
- Telik Announces Publication of a Case Report of a Sustained Hematologic Response in Myelodysplastic Syndrome Following an Abbreviated Exposure to Oral Telintra(R) (Ezatiostat HCl)
- PARI Pharma's Altera Delivers Gilead's Cayston in Head-to-Head Study With Tobramycin Inhalation Solution
June 22, 2010
- QLT Announces Final Results From Its RADICAL Study Evaluating Verteporfin PDT (Visudyne) Combination Therapy in Exudative AMD
- Six Presentations at the ADA Annual Meeting will Highlight Data on VIVUS' Qnexa
- New study shows that fosaprepitant dimeglumine is non-inferior to aprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV)
- Inovio Pharmaceuticals' Optimized DNA Vaccine Demonstrates Significant Advantages in Non-Human Primates Compared to Leading Viral Vector Based Vaccine
- Neurologix Announces Successful Phase 2 Trial of Gene Therapy for Parkinson's Disease
- Nuon Therapeutics Announces Results of Studies Confirming the Uric Acid Lowering Activity of Tranilast
- Results from Head-to-Head Trial: Azilsartan Medoxomil vs. Valsartan
- Access Pharma Sponsors Oral Mucositis Symposium Today for MASCC Conference Attendees
- NuPathe to Present Data for Zelrix at the 52nd Annual Scientific Meeting of the American Headache Society
- Survival Rate Up to 100% for Late Stage Treatment of Anthrax Infections
- Dapagliflozin as Monotherapy Demonstrated Improved Glycemic Control in Treatment-Naïve Adults with Type 2 Diabetes
- Rhythm's RM-493 Reverses Obesity and Insulin Resistance in Obese Primates
June 23, 2010
- Results from 3A Registry demonstrate significant systolic blood pressure lowering with Rasilez after one year
- MAP Pharmaceuticals Presents Analyses Showing LEVADEX Effective when Administered at Various Times in Migraine Cycle and in Patients with Concomitant Asthma
June 24, 2010
- Pharmaxis Announces Results For Second Phase III Trial Of Bronchitol In Cystic Fibrosis
- MediGene reports additional phase II results of EndoTAG-1 for the treatment of triple receptor-negative breast cancer
- Antihypertensive Drugs May Protect Against Alzheimer's Disease
- Helix BioPharma Corp. Announces Positive Phase II Pharmacokinetic Findings for Topical Interferon Alpha-2b in Patients With Low-Grade Cervical Lesions
- Cellonis Diabetes Stem Cell Therapy: A Chance for Insulin Independence and the Reversal of Complications
- Access Pharmaceuticals, Inc. Presents MuGard Clinical Experience at MASCC Conference
- Quark Pharmaceuticals Announces Presentations of its Two siRNA Drug Candidates at Glaucoma & Retinopathies 2010
June 25, 2010
- Theratechnologies Announces Publication of Combined Tesamorelin Phase 3 Results in JCEM
- Human Genome Sciences Announces Presentation of Additional Phase 3 SLE Study Results for Benlysta (Belimumab) at International Congress on SLE
- American Diabetes Association/The Lancet Symposium Will Highlight Study Showing Afrezza Provides Comparable Glycemic Control with Less Weight Gain and Hypoglycemia than Standard of Care
- Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax Administration
- Research Presented at the 9th International Lupus Congress Provides Hope and Encouragement for the Future Treatment and Management of Lupus
- Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
- Resverlogix Scientific Data Presented at EAS Congress
- Psychotropic medications can cause birth defects
June 28, 2010
- Sanofi's Lantus and Apidra Fares Better Against Premix Analog Insulin
- In a Post-Hoc Analysis, Januvia (sitagliptin), Merck's Diabetes Medicine, Compared with a Sulfonylurea (Glipizide) on Composite Endpoint of Lower Blood Sugar, No Hypoglycemia and No Weight Gain
- New High-Resolution Computer Tomography Data Demonstrates Evista's Effect on Bone Quality in Osteoporotic Patients
- Avila Therapeutics Presents New Btk Inhibitor Data at Federation of Clinical Immunology Societies Meeting, FOCIS 2010
- Alnylam Scientists and Collaborators Publish Research in Nature Chemical Biology on a Novel Mechanism for Regulation of Gene Expression with Anti-Gene RNAs (agRNAs)
- New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes
- Quark Pharmaceutical's QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model
- Zeria Pharmaceutical Announces the Results From Phase III, Double-Blind, Placebo-Controlled Study of Z-338 for Functional Dyspepsia Conducted in Japan
- Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
- Sixty-Two Year Old Chemotherapy Treatment Shows Promising Results on Progressive Multiple Sclerosis Patients
- CEL-SCI Collaborator Presents Data Showing LEAPS Vaccine Technology Generates Dendritic Cells That Can Protect Animals against Viral Illness and Other Diseases
- Study: Popular Diabetes Medications Not Associated With Increased Risk of Acute Pancreatitis
- Intarcia Therapeutics, Inc. Presents Positive ITCA 650 Phase 2 Study Results as a Late-Breaker at the American Diabetes Association 70th Scientific Sessions
- Ipsen's partner Roche confirms the promising efficacy profile of Taspoglutide
June 29, 2010
- Inovio Pharmaceuticals' Novel Gene Immunoadjuvant Significantly Improves DNA Vaccine Immune Responses in Non-Human Primates
- InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
- Forest Laboratories, Inc. and Gedeon Richter Announce Results from a Phase II Study of Radiprodil for the Treatment of Diabetic Peripheral Neuropathic Pain
- New Data for Vimpat (Lacosamide) C-V Showed Sustained Efficacy for Up to 5 Years and Improved Seizure Control When Added to a Broad Range of Antiepileptic Drugs
- Mirna Therapeutics Publishes Data Demonstrating In Vivo Proof of Concept for miR-34a microRNA Replacement Therapy in Cancer
- Bees Help to Beat MRSA Bugs
- Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim), Used in Phase 1/2 NSCLC and all Previous Trials
- Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
- ESHRE: Drinking Alcohol During Pregnancy May Damage Semen Quality in Sons
- Type 2 Diabetes Medication Rosiglitazone Associated With Increased Risk of Stroke, Heart Failure and Death, Compared to Pioglitazone
- Keryx Biopharmaceuticals' KRX-0401 (Perifosine) Data Selected for Oral Presentation at the Upcoming 12th World Congress on Gastrointestinal Cancer
- Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
- Sangamo BioSciences Presents Positive Phase 2 ZFP Therapeutic Data From SB-509 Programs in Diabetic Neuropathy at ADA 2010
- Aeolus Pharmaceuticals' AEOL 10150 Provides Significant Protection of Skin in Pre-Clinical Studies of Mustard Gas Exposure
- NIH-Supported Accord Eye Study Finds Two Therapies Slow Diabetic Eye Disease Progression
June 30, 2010
- NovaBiotics Ltd Excellent Unblinded Novexatin Phase IIa Data
- SciClone's Zadaxin Enhances H1N1 Vaccine in Critical First Six Weeks Post-Vaccination
- ADVENTRX Announces 9-Month Stability Data Results for ANX-530
- Cubist Announces All Objectives Met in Phase 2 CXA-101 Complicated Urinary Tract Infections Study
- Dacogen (Decitabine) for Injection Phase III AML Results Announced
- Eisai Announces Results of Phase III Study of Dacogen (Decitabine) for Injection in Acute Myeloid Leukemia (AML)
- BioSante Pharmaceuticals Announces Positive Clinical Results in Pill-Plus Oral Contraceptive Study
- Sepracor Reports Preliminary Results from a Second Phase III Study for Omnaris HFA Nasal Aerosol in Seasonal Allergic Rhinitis
- Tranzyme Pharma Announces Positive Results from Phase 2 Study of Oral TZP-102 (Ghrelin Agonist) in Patients with Diabetic Gastroparesis
